Sevabertinib, a potential treatment for HER2-mutant non-small cell lung cancer (NSCLC), has received priority review designation from the FDA. Christine Roth of Bayer highlighted the significance of this milestone, emphasizing the unmet need and potential of sevabertinib to improve outcomes for patients. If approved, sevabertinib could address critical unmet needs and offer hope to a patient population with limited treatment options and poor prognosis, particularly impacting women, younger individuals, and nonsmokers with HER2-mutant NSCLC.
Read more from targetedonc.com
